Functional Concept – Page 74

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

2 years ago talkbio0Tagged Accelerated, amgen, approval pathway, clinical benefits, confirmatory data, confirmatory trials, K-ras Oncogene, Myers, oncology therapies, squibb, United States Food and Drug Administration

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials

Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy

2 years ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, single-dose

Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials

BridgeBio’s Infigratinib Demonstrates Sustained Efficacy in Phase 2 Trial for Achondroplasia Treatment

2 years ago talkbio0Tagged Achondroplasia, BridgeBio, Growth Disorders, Hypochondroplasia (disorder), infigratinib, Phase 2 trial

BridgeBio, Infigratinib, Achondroplasia, Hypochondroplasia, Phase 2 Trial, Growth Disorder Treatment

ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment

2 years ago talkbio0Tagged 2024, ASCO, AstraZeneca, CheckMate-9DW, first-line, Immunotherapy, Liver and Intrahepatic Biliary Tract Carcinoma, Myers, Opdivo-Yervoy, Roche (company), squibb

ASCO 2024, Opdivo-Yervoy, Bristol Myers Squibb, Liver Cancer, First-Line Treatment, Roche, AstraZeneca, Immunotherapy, CheckMate-9DW

Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO

2 years ago talkbio0Tagged Akeso, ASCO, Ivonescimab, Keytruda, Malignant Neoplasms, Non-Small Cell Lung Carcinoma, PDCD1 gene, summit, Vascular Endothelial Growth Factor A

Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment

Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy

2 years ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, NTLA-2002, single-dose

Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data

AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment

2 years ago talkbio0Tagged Antibody-Drug Conjugates, ASCO, AstraZeneca, Carcinoma breast stage IV, Daiichi, Deruxtecan, Enhertu, Malignant neoplasm of breast, Sankyo, trastuzumab

Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

2 years ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA